Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17915728 | 0.85 | FDPS (0.58) | FDPSLMNAPDE3AADRB3PDE4D | |
| SCHEMBL15397158 | 0.77 | FDPS (0.58) | FDPSLMNAPDE3AADRB3PDE4D | |
| SCHEMBL8331999 | 0.76 | FDPS (0.56) | FDPSLMNASMPD1 | |
| SCHEMBL10389143 | 0.76 | LMNA (0.41) | FDPSLMNAPDE3AADRB3PDE4D | |
| SCHEMBL28403519 | 0.74 | LMNA (0.39) | FDPSLMNAPDE3AADRB3PDE4D | |
| SCHEMBL19212082 | 0.74 | GRM4 (0.58) | FDPSLMNAGRM4ALDH1A1BLM | |
| SCHEMBL5162874 | 0.72 | FDPS (0.64) | FDPSLMNAPDE3AADRB3PDE4D | |
| SCHEMBL11511845 | 0.72 | FDPS (0.52) | FDPSLMNAPDE3AADRB3PDE4D | |
| SCHEMBL7572194 | 0.72 | FDPS (0.42) | FDPSLMNAPDE3AADRB3PDE4D | |
| Pamidronic Acid SCHEMBL18361 | 0.70 | FDPS (1.00) | FDPSLMNAPDE3AADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | FDPS 4503/4885LMNA 4663/4885PDE3A 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.